SHMT2 and cancer: Targeting PHGDH, SHMT2, or other enzymes in the one-carbon metabolic pathway has not yet been proven to slow or halt tumor development in genetically modified, patient-derived xenografts (PDX), or syngeneic animal models of cancer.